COVID-19 Summary Guidelines

Main Article Content

Samuel Moses
Nidhika Berry
Professor Atul Kalhan
Sonia Sathe
Latha Srinivasan
Viju Varadarajan
Hasmukh Shah
Prof. Keshav Singhal MBE FLSW


Low and Medium Income Countries- May 2021

We note with concern, potential misinformation regarding treatment options is recommended to patients in India. We suggest the following evidence-based practice for the management of SARS CoV2 infection.

Article Details

How to Cite
Moses, S., Berry, N., Kalhan, A., Sathe, S., Srinivasan, L., Varadarajan, V., Shah, H., & Singhal, K. (2021). COVID-19 Summary Guidelines. Sushruta Journal of Health Policy & Opinion, 14(2), 1-5.
Author Biographies

Samuel Moses, Wales Health Board

Consultant in Virology & Infection

Nidhika Berry, Wales Health Board

Consultant in Microbiology

Professor Atul Kalhan, Wales Health Board

Consultant in Endocrinology

Sonia Sathe, Wales Health Board

Consultant in Intensive Care Medicine and Anaesthetics

Latha Srinivasan, Wales Health Board

Consultant in Anaesthetics

Viju Varadarajan, Wales Health Board

Consultant in Anaesthetics

Hasmukh Shah, Wales Health Board

General Practitioner

Prof. Keshav Singhal MBE FLSW, University of Swansea, Wales, UK

Consultant Orthopaedic Surgeon
Hon. Consul of Poland to Wales
Councilmember & Trustee Swansea University
Chair Bapio Wales
Governor India Centre Cardiff


1 RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021;384:693–704. doi:10.1056/NEJMoa2021436
2 The Writing Committee for the REMAP-CAP Investigators, Angus DC, Derde L, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA 2020;324:1317. doi:10.1001/jama.2020.17022
3 Corticosteroids for COVID-19. REMAP-CAP Trial. (accessed 1 Jun 2021).
4 Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Critical Care Medicine 2020;48:e440–69. doi:10.1097/CCM.0000000000004363
5 prone_position_in_adult_critical_care_2019.pdf. (accessed 1 Jun 2021).
6 Bamford P, Bentley A, Dean J, et al. ICS Guidance for Prone Positioning of the Conscious COVID Patient 2020. ;:6.
7 INSPIRATION Investigators, Mazloomzadeh S, Khaleghparast S, et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA 2021;325:1620. doi:10.1001/jama.2021.4152
8 CAS-ViewAlert. (accessed 1 Jun 2021).
9 Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) | The BMJ. (accessed 1 Jun 2021).
10 Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial | medRxiv. (accessed 1 Jun 2021).
11 Convalescent Plasma for COVID-19. REMAP-CAP Trial. (accessed 1 Jun 2021).
12 Convalescent plasma is ineffective for covid-19 | The BMJ. (accessed 1 Jun 2021).
13 Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 | NEJM. (accessed 1 Jun 2021).
14 azithromycin-recovery-statement-141220_final.pdf. (accessed 1 Jun 2021).
15 Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;:105949. doi:10.1016/j.ijantimicag.2020.105949
16 Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med Published Online First: 18 March 2020. doi:10.1056/NEJMoa2001282
17 Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet. (accessed 1 Jun 2021).
18 REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med 2021;384:1491–502. doi:10.1056/NEJMoa2100433
19 Group RC, Horby PW, Pessoa-Amorim G, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021;:2021.02.11.21249258. doi:10.1101/2021.02.11.21249258
20 Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis 2020;79:1277–85. doi:10.1136/annrheumdis-2020-218122
21 PINHO AC. EMA advises against use of ivermectin for the prevention or treatment COVID-19 outside randomised clinical trials. European Medicines Agency. 2021. (accessed 1 Jun 2021).
22 WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. (accessed 1 Jun 2021).
23 Chakravorty S. Vaccines against SARS-Cov-2: An Unprecedented Scientific Triumph and a Source of Hope in the Pandemic. phy 2021;6:1–3. doi:10.38192/
24 The effects of virus variants on COVID-19 vaccines. (accessed 1 May 2021).